There’s one less weight-loss drug on the market

I would like to provide an update to my article, “10 proven strategies to help patients maintain weight loss” (J Fam Pract. 2020;69:20-25), which mentioned lorcaserin as one of several medications approved by the US Food and Drug Administration (FDA) for long-term use in weight maintenance. On February 13, 2020, the FDA requested that the manufacturer of Belviq and Belviq XR (lorcaserin), Eisai Inc., voluntarily withdraw the weight-loss drug from the US market because a safety clinical trial demonstrated an increased occurrence of cancer. Eisai Inc. has submitted a request to voluntarily withdraw the drug. The FDA has advised patients to stop taking lorcaserin and talk to their health care provider about alternative weight-loss medicines and weight management programs.

Marijane Hynes, MD
Weight Management Program
The George Washington University
Medical Faculty Associates
Washington, DC

I would like to provide an update to my article, “10 proven strategies to help patients maintain weight loss” (J Fam Pract. 2020;69:20-25), which mentioned lorcaserin as one of several medications approved by the US Food and Drug Administration (FDA) for long-term use in weight maintenance. On February 13, 2020, the FDA requested that the manufacturer of Belviq and Belviq XR (lorcaserin), Eisai Inc., voluntarily withdraw the weight-loss drug from the US market because a safety clinical trial demonstrated an increased occurrence of cancer. Eisai Inc. has submitted a request to voluntarily withdraw the drug. The FDA has advised patients to stop taking lorcaserin and talk to their health care provider about alternative weight-loss medicines and weight management programs.

Marijane Hynes, MD
Weight Management Program
The George Washington University
Medical Faculty Associates
Washington, DC

I would like to provide an update to my article, “10 proven strategies to help patients maintain weight loss” (J Fam Pract. 2020;69:20-25), which mentioned lorcaserin as one of several medications approved by the US Food and Drug Administration (FDA) for long-term use in weight maintenance. On February 13, 2020, the FDA requested that the manufacturer of Belviq and Belviq XR (lorcaserin), Eisai Inc., voluntarily withdraw the weight-loss drug from the US market because a safety clinical trial demonstrated an increased occurrence of cancer. Eisai Inc. has submitted a request to voluntarily withdraw the drug. The FDA has advised patients to stop taking lorcaserin and talk to their health care provider about alternative weight-loss medicines and weight management programs.

Marijane Hynes, MD
Weight Management Program
The George Washington University
Medical Faculty Associates
Washington, DC